CytoDyn (CYDY) Total Current Liabilities (2011 - 2026)
CytoDyn's (CYDY) quarterly Total Current Liabilities came in at $50.4 million in Q1 2026, down 28.54% YoY from $70.6 million in Q1 2025, and down 40.75% on a QoQ basis from $85.1 million in Q4 2025.
CytoDyn (CYDY) Total Current Liabilities (2011 - 2026) Analysis & Trends
CytoDyn (CYDY) has 16 years of Total Current Liabilities data on file, last reported at $50.4 million in Q1 2026.
- Quarterly Total Current Liabilities fell 28.54% year-over-year to $50.4 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $50.4 million (down 28.54% YoY) and the FY2025 annual result came in at $70.5 million, down 16.23% from the prior year.
- Total Current Liabilities retreated to $50.4 million in Q1 2026, from $85.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $129.5 million in Q1 2024 to a low of $50.4 million in Q1 2026.
- A 5-year average of $98.7 million and a median of $116.1 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities slumped 46.1% — and 2025, when it rose 20.51%.
- Tracing CYDY's Total Current Liabilities over 5 years: stood at $122.7 million in 2022, then rose by 0.59% to $123.4 million in 2023, then sank by 42.77% to $70.6 million in 2024, then climbed by 20.51% to $85.1 million in 2025, then slumped by 40.75% to $50.4 million in 2026.
- The last three Total Current Liabilities figures came in at $50.4 million (Q1 2026), $85.1 million (Q4 2025), and $69.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | 50.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 50.43 Mn |
| Nov 30, 2025 | 85.11 Mn |
| Aug 31, 2025 | 69.42 Mn |
| May 31, 2025 | 70.52 Mn |
| Feb 28, 2025 | 70.57 Mn |
| Nov 30, 2024 | 70.63 Mn |
| Aug 31, 2024 | 69.56 Mn |
| May 31, 2024 | 84.18 Mn |
| Feb 29, 2024 | 129.48 Mn |
| Nov 30, 2023 | 123.41 Mn |
| Aug 31, 2023 | 129.05 Mn |
| May 31, 2023 | 119.80 Mn |
| Feb 28, 2023 | 121.33 Mn |
| Nov 30, 2022 | 122.69 Mn |
| Aug 31, 2022 | 122.32 Mn |
| May 31, 2022 | 123.16 Mn |
| Feb 28, 2022 | 116.09 Mn |
| Nov 30, 2021 | 115.91 Mn |
| Aug 31, 2021 | 129.64 Mn |
| May 31, 2021 | 152.55 Mn |